论文部分内容阅读
根据浙江升华拜克股份有限公司年度财务报表(附后)分析如下: 公司主导产品双黄连口服液受到较大的市场冲击 该公司是生物化工行业的一家高新技术企业,2000年在生产经营过程中,充分发挥了科技优势,注重主导产品的科技含量,并深入开发研究新产品,积极拓展出口销售市场。因而,尽管主导产品之一伊维菌素的市场竞争激烈,价格有下降风险,在获益方面仍取得了可喜的成绩。主营业务收入在上年取得良好成绩的基础上又迈了一个新台阶;主营业务利润、净
According to the annual financial statements of Zhejiang Shenghua Baike Co., Ltd. (attached), the analysis is as follows: Shuanghuanglian Oral Liquid, a leading product of the Company, is greatly impacted by the market. The company is a high-tech enterprise in the biochemical industry. In 2000, during its production and operation , Give full play to the advantages of science and technology, pay attention to the scientific and technological content of leading products, and in-depth research and development of new products, and actively expand the export sales market. Thus, despite the fierce market competition and the declining price of ivermectin, one of the leading products, there have been some encouraging achievements in terms of benefits. Main business income in the previous year achieved good results on the basis of another step to a new level; main business profit, net